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Abstract
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) was first reported in
remote regions of Western Australia and is now the predominant MRSA isolated in the state. The objective of this
study is to determine the genetic relatedness of Western Australian CA-MRSA clones within different multilocus
sequence type (MLST) clonal clusters providing an insight into the frequency of S. aureus SCCmec acquisition
within a region.
Results: The CA-MRSA population in Western Australia is genetically diverse consisting of 83 unique pulsed-field
gel electrophoresis strains from which 46 MLSTs have been characterised. Forty five of these sequence types are
from 18 MLST clonal clusters and two singletons. While SCCmec IV and V are the predominant SCCmec elements,
SCCmec VIII and several novel and composite SCCmec elements are present. The emergence of MRSA in diverse S.
aureus clonal clusters suggests horizontal transmission of the SCCmec element has occurred on multiple occasions.
Furthermore DNA microarray and spa typing suggests horizontal transfer of SCCmec elements has also occurred
within the same CC. For many single and double locus variant CA-MRSA clones only a few isolates have been
detected.
Conclusions: Although multiple CA-MRSA clones have evolved in the Western Australian community only three
clones have successfully adapted to the Western Australian community environment. These data suggest the
successful evolution of a CA-MRSA clone may not only depend on the mobility of the SCCmec element but also
on other genetic determinants.
Background
Based on phenotypic and genotypic typing methods,
community onset methicillin-resistant Staphylococcus
aureus infections are caused by healthcare-associated
MRSA (HA-MRSA) strains, which appear to have been
transferred from hospitals or healthcare facilities into
the community by patients or healthcare workers [1], or
by community-associated MRSA (CA-MRSA) strains,
which have been isolated from people who have had lit-
tle or no contact with healthcare facilities or healthcare
w o r k e r s[ 2 ] .T h i sd i s t i n c t i on between community and
healthcare facility however has become blurred with the
replacement of HA-MRSA with CA-MRSA in hospitals
[3,4].
In contrast to HA-MRSA, CA-MRSA strains are gen-
erally more susceptible to non beta-lactam antibiotics,
grow significantly faster, have different clonal back-
grounds, carry smaller staphylococcal cassette chromo-
some mec (SCCmec) elements (most commonly
SCCmec type IV or type V), have enhanced virulence
properties and frequently harbor genes expressing Pan-
ton-Valentine leukocidin (PVL) [5-8]. Rather than a
worldwide spread of a single clone multiple CA-MRSA
clones have emerged from diverse genetic backgrounds.
Several well characterized CA-MRSA clones predomi-
nate in different regions: Sequence type (ST) 8-IV [2B]
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[9,10]; ST80-IV [2B] (European clone) in Europe [8],
North Africa [11] and the Middle East [12]; ST59-V
[5C2&5] (Taiwan clone) in Taiwan [13]; ST93-IV [2B]
(Queensland clone) in Australia [14], ST30-IV [2B]
(South West Pacific [SWP] CA-MRSA) in the Western
Pacific [15,16], and ST772-V [5C2] (Bengal Bay clone)
in India and Bangladesh [17]. Transmission of these
clones into other regions has occurred [18,19]. This
occurrence of concurrent epidemics of CA-MRSA in
many countries by different clones has been striking.
Equally noteworthy are a number of common features
of these epidemics, prominent among them the ability
to cause severe infections in young otherwise healthy
people and the carriage of the lukF-PV/lukS-PV PVL
encoding genes by the organism.
The earliest report of CA-MRSA infections involved
indigenous people living in remote communities in the
sparsely populated Kimberley region of Western Austra-
lia (WA) [20]. Approximately 50% of the people in this
region are indigenous, many of whom live in poor socio-
economic conditions. Infected skin lesions and staphylo-
coccal sepsis occur frequently and empirical
antistaphylococcal therapy is often prescribed. Colloqui-
ally known as “WA-MRSA”, the early isolates have a
similar pulsed-field gel electrophoresis (PFGE) pattern
and have subsequently been characterized as a single
clone; PVL-negative WA5 (ST8-IV/spa t008) [21]. By
2006 22 CA-MRSA clones were identified in WA, with
PVL-negative WA 1 (ST1-IV [2B]/t127) replacing WA5
as the predominant clone [22]. At this time CA-MRSA
from indigenous people living in remote areas outside of
WA were reported in the Northern Territory [23],
Queensland [24] and Central Australia [25]. As may be
expected in a geographically large country with relatively
few dense concentrations of population, often separated
by large areas of desert, different CA-MRSA clones
evolved in these communities.
In 1982 colonization or infection with MRSA became
a notifiable condition in WA. For infection control pur-
poses all MRSA isolated in the state since 1997 have
been referred to the Australian Collaborating Centre for
Enterococcus and Staphylococcus Species (ACCESS) Typ-
ing and Research where based on molecular markers
they are characterized as either HA-MRSA or CA-
MRSA [26]. Although a state-wide policy of screening
all patients and healthcare workers who have lived out-
side the state for MRSA has prevented HA-MRSA from
becoming endemic in Western Australian hospitals, it
has not prevented CA-MRSA from becoming estab-
lished in the community. In WA the public health sys-
tem is divided into two metropolitan health regions and
seven country health regions. The state encompasses an
area of 1.02 million square miles and has a population
of approximately 2.24 million people. In 1983, the over-
all rate of MRSA notifications was 10 per 100,000 per-
sons in the rural country health regions and 7/100,000
in the metropolitan regions [27]. By 2006 notifications
rates throughout the state had increased to 179/100,000
persons of which 144/100,000 were CA-MRSA. In the
metropolitan health regions the CA-MRSA notification
rate was 134/100,000 whilst in the Kimberley health
region the CA-MRSA notification rate had increased 40-
fold to 391/100,000 [18].
CA-MRSA is thought to emerge when a locally preva-
lent strain of methicillin susceptible S. aureus (MSSA)
acquires a SCCmec element and utilizes mobile genetic
elements and single nucleotide polymorphisms to estab-
lish local and geographic niches [28]. As WA is a
remote region in which all MRSA isolates are referred
to a central typing laboratory it is an ideal environment
t os t u d yt h ee m e r g e n c ea n de v o l u t i o no fC A - M R S A .
MLST, SCCmec, spa typing and microarray DNA is per-
formed on all isolates with a unique PFGE pulsotype.
The aim of this study is to determine the genetic relat-
edness of WA CA-MRSA clones within different MLST
clonal clusters (CC) providing an insight into the fre-
quency of S. aureus SCCmec acquisition within a region.
The genetic profile of these clones may also offer an
explanation why only a few WA CA-MRSA clones have
successfully adapted to the community environment.
Results
The 83 unique PFGE strains isolated in Western Austra-
lia from 1989 to 2010 were nuc and mecA gene positive
by PCR. The DNA microarray S. aureus species markers
gapA (glyceraldehyde 3-phosphate dehydrogenase) and
rrn STAU (S. aureus ribosomal marker) were detected
in all strains. The array’sl i n e a rp r i m e re l o n g a t i o n
method detected the katA (catalase A), coA (coagulase),
nuc, spa (protein A) and sbi (IgG-binding protein) S.
aureus species markers in 78 strains. These markers
were either not detected or detected only by random
amplification in five strains (WA8, WA47, WA72,
WA76 and WA79).
F o r t ys i xS T sw e r ei d e n t i f i e db yM L S T .U s i n gt h e
MLST website’s eBURST V3 algorithm 45 STs were
grouped into 18 CCs and two singletons (Figure 1). The
CC for WA76 (ST1303) has not been determined.
Several SCCmec types and subtypes, novel SCCmecs,
and composite SCCmecs were identified. Forty five
strains harbor SCCmec IVa-d [2B] (31 IVa, 2 IVb, 9
IVc, 3 IVd), 12 strains SCCmec V [5C2] and two
strains SCCmec VIII [4A]. Two strains have non type-
able SCCmec IV subtypes and four strains have a
SCCmec element with a novel ccr gene complex
including three with a class B mec gene complex and
one with a class A mec complex. Eighteen strains
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complexes including 12 with SCCmec V [5C2&5] (5C2
plus ccrC1 allele 8), three with SCCmec IVa [2B]&5
(2B plus a type 5 ccr gene complex), one with V (5C2)
&2 (5C2 plus a type 2 ccr gene complex) and two with
V [5C2&5]&2 (a composite SCCmec V element plus a
type 2 ccr gene complex).
The MLST, spa type, agr type, capsule type, SCCmec,
antibiogram, resistance genotype, lukF/S-PVL genes,
enterotoxin genes and bacteriophage associated viru-
lence genes of each unique PFGE strain are provided in
Additional File 1. Information on target genes, probes,
and primers is provided in Additional File 2. Complete
hybridization profiles for the individual strains can be
provided on request.
Clonal Complex 1
CC1 contains five strains including the PVL positive
Bengal Bay clone (ST772 [a single locus variant {slv} of
ST1]-V [5C2]/t3387). This strain is epidemiologically
linked to a healthcare worker from India and is not con-
sidered a WA CA-MRSA.
Based on the agr/capsule and SCCmec type, the
remaining four strains are divided into two groups:
Group 1
agr type III/capsule type 8 SCCmec IVa [2B] contains
PVL negative WA1 (ST1/t127), WA45 (ST872 [slv of
ST1]/t127), and WA57 (ST1005 [ST1 slv]/t127). WA1
and WA45 harbor a ccrA-1 and ccB-1 gene complex
and Q6GD50 (fusidic acid resistance marker) indicating
the presence of the mobile fusidic acid SCC element
SCCfur. WA1 is known to carry multiple plasmids such
as a 2-kb plasmid encoding resistance to erythromycin
[29] and this presumably accounts for the differences in
the antibiogram and resistance genotype for WA1,
WA45 and WA57. In addition to enterotoxin genes the
three strains harbor a type D immune evasion cluster
[IEC] (seA+sak+scn) [30]. Group 2
agr type II/capsule type 5 SCCmec V [5C2] contains
P V Ln e g a t i v eW A 1 0( S T 5 7 3[ S T 1s l v ] / t 5 0 7 3 .W A 1 0
Figure 1 eBURST generated population snapshot of CA-MRSA clones isolated in Western Australia (http://www.mlst.net/).E a c h
sequence types (STs) is represented by a black dot. The ancestral ST of a clonal complex is represented by a blue dot. The size of the dot
reflects the number of WA CA-MRSA clones with this ST. STs that diverge at no more than one of the seven MLST loci belong to the same
clonal complex. Double locus variants (DLVs) are included if the linking single locus variant (SLV) was present in the MLST database. SLVs and
DLVs of a sequence type are represented by pink and blue line respectively. Purple lines represent overlapping pink and blue lines.
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toxin egc cluster [seG+seI+seM+seN+seO+seU/Y]).
Unlike WA1, WA45 and WA57, WA10 does not carry
t h et y p eDI E C ,t h ep a t h o g e n i city island harboring the
leukocidin D/E component, the protease splA gene and
the hsdS gene. The ssl/set genes and cell surface adhe-
sions encoding genes of WA10 are closely related to the
Bengal Bay clone.
Clonal Complex 5
CC5 contains 27 strains. Based on the agr/capsule type
the isolates are divided into two groups which are
further divided into subgroups based on the SCCmec
type.
Group 1
agr type I/capsule type 8 (2 strains)
i. SCCmec IVa [2B] contains WA51 (ST6 [ST5
dlv]). The protein A variable region in WA51
could not be amplified and therefore a spa type
cannot be allocated.
ii. SCCmec IVa [2B]&5 contains WA66 (ST6/
t701).
WA51 and WA66 harbor a type D IEC Neither
strain harbors the lukF-PV/lukS-PV PVL encoding
genes.
Group 2
agr type II/capsule type 5 (25 strains)
Unlike Group 1 strains, these 25 strains harbour the
enterotoxin egc cluster. Ten spa types were identi-
fied, of which nine are closely related: t002, t045,
t071, t442, t688, t1265, t2666, t3378, t4065.
i. SCCmec IVa [2B] contains WA3 (ST5/t002),
WA64 (ST5/t3778), WA71 (ST5/t002), WA82
(ST5/t002), WA25 (ST575 [ST5slv]/t002), WA50
(ST73 [ST5slv]/t002) and WA65 (ST73/t002). PVL
negative WA3, WA71, WA82, WA25, WA50 and
WA65 harbor a type F IEC (seP+sak+chp+scn).
PVL positive WA64 harbors a type A IEC (seA+sak
+chp+scn). WA64 and WA65 also harbor edinA
(epidermal cell differentiation inhibitor A gene).
ii. SCCmec IVc [2B] contains PVL negative
WA74 (ST5/t002) which harbors a type F IEC.
iii. SCCmec IV [2B] contains PVL negative
WA39 (ST526 [ST5slv]/t4065) which has a non
typeable SCCmec IV [2B] element and a type B
IEC (sak+chp+scn).
iv. SCCmec V [5C2] contains PVL negative
WA14 (ST5/t442), WA35 (ST5/t688), WA81
(ST5/t045) [a non related spa type] and WA90
(ST5/t1265). WA81 harbors a type F IEC; WA14
and WA90 a type G IEC (seP+sek+scn)a n d
WA35 a type B IEC.
v. SCCmec V [5C2&5] contains PVL negative
WA11 (ST5/t045), WA86 (ST5/t002), WA34
(ST5/t458), WA80 (ST5/t071), WA85 (ST5/
t2666), and WA87 (ST835 [ST5slv]/t002). WA85
and WA86 harbor a type F IEC; WA34, WA80
and WA87 a type B IEC and WA11 a type E IEC
(sak + scn). WA80 harbors the ACME (arginine
catabolic mobile element) genes.
vi. SCCmec V [5C2]&2 contains PVL negative
WA61 (ST641 [ST5slv]/t002) which harbors a
type E IEC.
vii. SCCmec V [5C2&5]&2 contains PVL negative
WA40 (ST835 [ST5slv]/t002) and WA46 (ST835/
t002). WA40 harbors a type B IEC while WA46
a type E IEC.
viii. SCCmec novel [novel B] contains PVL nega-
tive WA18 (ST5/t002), WA21 (ST5/t002) and
WA48 (ST835/t002) harboring ccrA-1 and a
class B mec complex (mecA and a truncated
mecR1 genes). WA18 harbors a type F IEC;
WA21 a type D IEC; and WA48 a type B IEC.
Clonal Complex 8
The 12 CC8 strains are all agr type I/capsule type 5.
Seven closely related spa types were identified: t008,
t024, t064, t334, t711, t1635, t2238.
The CC8 strains include the ST8-MRSA-IVc [2B]/t008
USA300 MRSA clone [31]. Based on the SCCmec type
the remaining 11 strains are divided into seven sub-
groups:
i. SCCmec IVa [2B] contains WA5 (ST8/t008), WA6
(ST8/t008), WA62 (ST923 [ST8slv]/t1635), and
WA83 (ST1634 [ST8slv]/t711). WA5, WA62, and
W A 8 3h a r b o rat y p eBI E C .A nI E Cw a sn o t
detected in WA6. Unlike the other WA CC8 strains,
WA62 is PVL positive.
ii. SCCmec IVd [2B] contains WA58 (ST1173
[ST8slv]/t064) and WA20 (ST612 [ST8dlv]/t064)
which harbor a type D IEC.
iii. SCCmec IVa [2B]&5 contains WA92 (ST1757
[ST8slv]/t024) which does not harbor an IEC.
iv. SCCmec IV [2B] contains WA31 (ST576
[ST8slv]/t334) which does not harbor an IEC. The
SCCmec IV element is non typeable.
v. SCCmec V [5C2] contains WA77 (ST8/t008)
w h i c hh a r b o r sat y p eDI E C ,t h eA C M Ed e t e r m i -
nant, and SCCfus.
vi. SCCmec V ([5C2&5]) contains WA53 (ST8/
t2238) which harbors a type D IEC.
vii. SCCmec VIII (4A) contains WA16 (ST8/t024)
which harbors a type D IEC.
Coombs et al. BMC Microbiology 2011, 11:215
http://www.biomedcentral.com/1471-2180/11/215
Page 4 of 12Clonal Complex 12
CC12 contains two agr group II/capsule type 8
strains which harbor a type G IEC. Neither strain
harbor the lukF-PV/lukS-PV PVL encoding genes.
Based on the SCCmec type the two strains are
divided into two subgroups:
i. SCCmec IVa [2B] contains WA69 (ST12/t160).
ii. SCCmec novelA contains WA59 (ST12/t160)
which harbors a class A mec complex (mecA,
complete mecR1 and mecI regulatory genes). The
ccr genes were not detected by DNA microarray
and did not amplify with PCR primers.
Clonal Complex 30
CC30 contains two agr group III/capsule type 8 strains:
PVL positive ST30-IVc [2B]/t019 and PVL negative
WA68 (ST39 [ST30dlv]-IVc [2B]/t2643). Their protease,
haemolysin, leukocidin, ssl/set, hsdS, and cell surface
adhesion profiles are not homogeneous and their spa
types are not closely related.
The DNA microarray profile of ST30-IVc [2B]/t019 is
homogeneous with the South Western Pacific (SWP)
ST30-IV clone as is therefore not considered a WA CA-
MRSA.
WA68 harbors a type D IEC and tst-1genes.
Clonal Complex 45
CC45 contains four PVL negative strains. Based on the
agr group/capsule type the four isolates are divided into
two groups which are further divided into subgroups
based on the SCCmec type.
Group 1
agr group I/capsule 8 (two strains)
i. SCCmec IVa [2B] contains WA75 (ST45/t1424).
ii. SCCmec V [5C2] contains WA4 (ST45/t123)
which harbors tst1 genes.
Both strains harbor a type B IEC. The spa types
are not closely related.
Group 2
agr group IV/capsule type 8 (two strains)
i. SCCmec IVc [2B] contains WA23 (ST45/t1575)
ii. SCCmec V [5C2&5] contains WA84 (ST45/t1081).
Both strains harbor a type B IEC and closely
related spa types.
Clonal Complex 59
CC59 agr type I/capsule type 8 contains seven strains.
The DNA microarray profiles of ST59/ST952-V
[5C2&5] t437/t1950 are homogeneous with the Taiwan
clone and therefore are not considered WA CA-MRSA
[32].
Based on the SCCmec types the remaining five strains
are divided into three subgroups:
i. SCCmec IVa [2B] contains PVL positive WA55
and WA56 (ST59/t437). WA55 harbors a type B IEC
while WA56 a type A IEC.
ii. SCCmec IVb [2B] contains two PVL negative
strains with unrelated spa types: WA73 (ST59/t528)
and WA24 (ST87 [ST59slv]/t216). WA73 harbors a
type C IEC (chp+scn) and WA24 a type B IEC.
iii. SCCmec IVa [2B]&5 contains PVL negative
WA15 (ST59/t976) which harbors a type A IEC.
Clonal Complex 72
CC72 contains two agr group I/capsule type 5 strains
with closely related spa types. Based on the SCCmec
type the two strains are divided into two subgroups:
i. SCCmec IVa [2B] contains PVL positive WA44
(ST72/t791) harboring a type B IEC.
ii. SCCmec V (5C2) contains PVL negative WA91
(ST72/t3092) harboring a type E IEC and tst1 genes.
Clonal Complex 75
CC75 contains three PVL negative strains which are agr
group/capsule nontypeable by DNA microarray: WA8
(ST75-IVa [2B]), WA79 (ST75-IVa [2B]) and WA72
(ST1304 [ST75slv]-IVa [2B]) [33]. The three strains have
the same spa sequence (259-23-23-17-17-17-23-23-23-
17-16) which has not been allocated a spa type number
by the Ridom website. The three strains harbor a type E
IEC.
Clonal Complex 80
CC80 contains three PVL positive agr group III/capsule
type 8 strains: ST80-IVc [2B]/t044, ST583 [ST80slv]-IVc
[2B]/t044, and ST728 [ST80slv]-IVc [2B]/t044. The
DNA microarray virulence profiles are identical with the
European ST80-IV [2B] clone and therefore the three
strains are not considered WA CA-MRSA.
Clonal Complex 97
CC97 contains two PVL negative agr group I/capsule type
5 strains with closely related spa types: WA54 (ST953
[ST97dlv]-IVa [2B]/t359) and WA63 (ST1174[ST97dlv]-
IVa [2B]/t267). The strains harbor a type E IEC.
Clonal Complex 121
CC121 contains two PVL negative agr group IV/capsule
type 8 strains with closely related spa types. The two
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type, are divided into two subgroups:
i. SCCmec V [5C2] contains WA22 (ST577 [ST121
dlv]/t3025) which harbors etA (exfoliative toxin sero-
type A) and edinA genes.
ii. SCCmec V [5C2&5] contains WA93 (ST121/t159).
Clonal Complex 188
CC188 contains two PVL negative agr group I/capsule
type 8 strains: WA38 and WA78 (ST188-IVa [2B]/t189).
The two strains have a type B IEC.
Clonal Complex 361
CC361 contains three PVL negative agr group I/capsule
type 8 strains. The spa types are closely related. Based
on the SCCmec type the three strains are divided into
three subgroups:
i. SCCmec IVa [2B] contains WA29 (ST672
(ST361slv)/t1309) which harbors a type E IEC and
tst1 genes.
ii. SCCmec V [5C2] contains WA70 (ST672/t1309).
iii. SCCmec VIII [4A] contains WA28 (ST361/t315)
which harbors a type B IEC.
The following CCs contained a single strain:
Clonal Complex 9
PVL negative WA13 (ST834-IVc [2B]/t3029) is agr
group I/capsule type 8 and harbors a type B IEC and
tst1 genes.
Clonal Complex 88
PVL negative WA2 (ST78-IVa [2B]/t3205) is agr group
III/capsule type 8 and harbors a type B IEC.
Clonal Complex 152
PVL positive WA89 (ST1633-V [5C2]/t355) is agr group I/
capsule type 5 and harbors a type E IEC and edinB genes.
Clonal Complex 398
Although PVL negative ST398-V [5C2&5]/t034 is fre-
quently associated with livestock, the strain is increas-
ingly isolated from human patients [34]. Rarely
identified in Australia, the DNA microarray profile of
this isolate is homogeneous with the European live-
stock-associated ST398 strain and is therefore not con-
sidered a WA CA-MRSA.
WA76 (Clonal Complex not Determined)
PVL negative WA76 (ST1303-IVa [2B]) is agr group III
with a non typeable capsule by DNA microarray. The
spa sequence (259-25-17-17-16-16-16-16) has not been
allocated a spa type number by the Ridom website.
Queensland Clone (Singleton)
PVL positive ST93-IVa [2B]/t202 is agr group III/cap-
sule type 8 and harbors a type B IEC. The DNA micro-
array profile is homogeneous with the Queensland
clone. Due to its origin and widespread distribution out-
side WA the Queensland clone is not considered a WA
CA-MRSA.
WA47 (Singleton)
PVL negative WA47 (ST883-IVd [2B]/t7462) has a non
typeable agr group/capsule type by DNA microarray.
Discussion
As all MRSA isolated in WA are referred to a central
typing laboratory it is possible to investigate the emer-
gence and evolution of CA-MRSA in a remote region.
Prior to the global evolution and expansion of CA-
MRSA, five CA-MRSA clones were identified in the
indigenous population living in the remote communities
of the sparsely populated Kimberley, Pilbara and Eastern
Goldfield regions of WA [29]. These five PVL negative
clones include: WA1 (CC1: ST1-IVa [2B]/t127), WA2
(CC88: ST78-IVa [2B]/t3205), WA3 (CC5: ST5-IVa
[2B]/t002), WA4 (CC45 ST45-V (5C2)/t123) and WA5
(CC8: ST8-IVa [2B]/t008). WA5 and WA1 were origin-
ally isolated from clinical specimens in 1989 and 1995
respectively, and WA2, WA3 and WA4 from nasal car-
riage specimens in 1995. The emergence of CA-MRSA
clones in different MLST clonal clusters indicates hori-
zontal transmission of the SCCmec element into S. aur-
eus has occurred on at least five occasions in these
remote communities: SCCmec IVa [2B] into CC1 (ST1),
CC5 (ST5), CC8 (ST8), CC88 (ST78), and SCCmec V
[5C2] into CC45 (ST45). Based upon the spa type and
the DNA microarray profile at least six evolutionary
events have occurred on at least three occasions from
these clones (ie vertical transmission of the SCCmec ele-
ment): twice from WA1, WA3 and WA5 (Figure 2).
Vertical transmission of the SCCmec element has not
been identified for WA4 or WA2.
The emergence of WA1, WA2 and WA3 has been due
to the acquisition and insertion of the small and highly
mobile type IVa [2B] SCCmec element, presumably har-
bored by methicillin resistant coagulase negative staphylo-
cocci (MRCNS). Several hypotheses to explain the
transmission of a SCCmec element from MRCNS to S.
aureus have been proposed including the increased use of
antimicrobials within a community [35]. Many of the Kim-
berley indigenous population live in poor socioeconomic
conditions. Staphylococcal skin lesions, commonly result-
ing from scabies infestation, trachoma and venereal
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quently in this population. Consequently empirical therapy
using b-lactamase stable penicillins and azithromycin is
often prescribed [36]. The frequent use of these antimicro-
bials may have assisted in the acquisition of the SCCmec
element and erm genes into S. aureus.G e n e t i cs t u d i e s
however have shown these newly emerged CA-MRSA
clones did not originate in the predominant methicillin-
susceptible S. aureus (MSSA) clones found in these com-
munities, suggesting not all clones are able to acquire or
retain the SCCmec element [37]. The subsequent dissemi-
nation of WA1, WA2 and WA3 into the wider community
suggests the acquisition of the SCCmec element and the
erm genes has given these clones a selective advantage.
WA4 and WA5 however have not been successful in
spreading beyond the indigenous communities suggesting
the acquisition of the SCCmec element does not provide a
universal selective advantage.
Many of the remaining 46 CA-MRSA clones, identi-
fied between July 2003 and June 2010, were not isolated
in remote WA indigenous communities. The geographi-
cal spread of CA-MRSA over long distances and across
cultural borders is believed to be a rare event compared
to the frequency in which the SCCmec element is
acquired by S. aureus [38]. Most of these clones are
therefore likely to have evolved in WA. Some clones are
slvs and dlvs of pre-existing CA-MRSA, and their
SCCmec type, spa type and DNA microarray profile sug-
gests vertical transmission of the SCCmec element has
occurred. However the emergence of MRSA in several
unrelated S. aureus clonal clusters suggests horizontal
transmission of the SCCmec element has also occurred.
SCCmec typing and spa typing and DNA microarray
results also suggests horizontal transfer of SCCmec ele-
ments has occurred into the same CC on more than
one occasion.
Although several SCCmec elements have been
acquired by multiple S. aureus clones from which many
CA-MRSA clones have emerged, only a few clones have
successfully adapted to the WA community
Figure 2 Proposed evolution of CA-MRSA from WA-1 (ST1-MRSA-IV), WA-3 (ST5-MRSA-IV) and WA-5 (ST8-MRSA-IV).
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Page 7 of 12environment. Between July 2009 to June 2010 4,691
MRSA were referred to ACCESS Typing and Research
of which 3,931 were characterized as CA-MRSA. Overall
84% (3,024) of isolates were from clinical infections and
the 16% (907) from colonized patients. Approximately
88% of CA-MRSA were identified as WA1 (40%), WA2
(24%) and WA3 (8%). For most clones, including WA4
and WA5 only a few isolates were detected. (http://
www.public.health.wa.gov.au/3/896/3/camrsa.pm).
For many slv and dlv CA-MRSA only a small number
of isolates have been detected suggesting changes in the
housekeeping genes may have conferred a fitness cost or
did not allow the SCCmec element to be maintained.
For example WA45 and WA57 are slvs of ST1 and their
SCCmec and spa type and DNA microarray profile sug-
gest they have evolved from WA1 (Figure 2). WA45 was
first identified in 2006 and WA57 in 2007. Although
WA1 has become the most successful CA-MRSA clone
in the WA community only one isolate of WA45 and
two isolates of WA56 have so far been identified (http://
www.public.health.wa.gov.au/3/896/3/camrsa.pm).
Six PVL positive pandemic CA-MRSA clones (plus
three closely related clones) have been isolated in WA:
Bengal Bay CA-MRSA (ST772-V [5C2]/t3387), USA300
MRSA (ST8-IVc [2B]/t008), SWP CA-MRSA (ST30-IVc
[2B]/t019), Taiwan CA-MRSA (ST59-V [5C2&5]/t437
and the slv ST952-V [5C2&5]/t1950), European CA-
MRSA (ST80-IVc [2B]/t044 and the slvs, ST583-IVc
[2B]/t044 and ST728-IVc [2B]/t044), and the Queens-
land CA-MRSA (ST93-IVa [2B]/t202). The epidemiology
of the USA300 and Taiwan CA-MRSA clones in WA
and the Queensland and SWP CA-MRSA clones in Aus-
tralia have previously been reported [18,31,32]. Patients
colonized or infected with the Bengal Bay clone have
been observed to be epidemiologically linked to Indian
healthcare workers (unpublished data). The USA300,
European, Taiwanese and Bengal Bay CA-MRSA clones
are not frequently isolated in WA. This may be due, in
part, to WA Health Department infection control inter-
ventions applied to patients who are colonized or
infected with international PVL positive pandemic
clones. A seventh pandemic clone has recently been
identified. The DNA microarray profile and the SCCmec
element of the PVL negative ST398-V [5C2&5] is indis-
tinguishable from the pandemic ST398 clone initially
isolated from pigs and pig farmers in the Netherlands
[39]. Only one isolate, from a patient with travel outside
of Australia, has been identified in WA.
The Queensland clone (ST93-IVa [2B]) first detected
on the east coast of Australia in the Caucasian popula-
tion in 2000 [40], has become one of the most prevalent
CA-MRSA isolated in Australia [18] and in 2010
accounted for 18% of CA-MRSA in WA. This suggests
the acquisition of the SCCmec element has given this
clone a selective advantage. Although the Queensland
c l o n ei sb e l i e v e dt oh a v eb e e ni n t r o d u c e di n t oW Ai n
2001 [22], PVL positive ST93-MSSA was identified as
the most prevalent S. aureus clone in WA’s remote indi-
genous communities in surveys performed in the mid
1990s. Although found in an environment of high b-lac-
tam use a methicillin-resistant variant of ST93-MSSA
was not found in WA during these surveys.
WA1, WA2 and WA3 are PVL negative and do not
harbor multiple virulence genes (Tables 1). Similarly the
successful Queensland clone, although PVL positive, car-
ries almost no other exotoxin genes and no additional
resistance genes. Although most other WA CA-MRSA
clones are also PVL negative, many of these clones have
acquired multiple resistance and/or virulence determi-
nants (Tables 1). For example WA78 (ST188-IVa [2B]/
t315) in addition to mecA and blaZ, harbors aacA-aphD,
tetK and cat and is phenotypically resistant to erythromy-
cin, trimethoprim and ciprofloxacin; WA64 (ST5-IVa
[2B]/t3778) has acquired seA enterotoxin genes and
edinA and lukF-PV lukS-PV virulence genes; and WA62
(ST923[ST8slv]-IVa [2B]/t1635) harbors seD+seJ+seR and
seK+seQ enterotoxin genes and lukF-PV lukS-PV.T h e
acquisition of multiple resistance and/or virulence genes
m a yh a v ec o m ea tah i g hf i t n e s sc o s ta sn o n eo ft h e s e
clones have established a niche in the WA community.
As WA1, WA2 and WA3 CA-MRSA lack PVL as well
as other virulence genes that are found in pandemic
international CA-MRSA clones, such ACME in USA300,
the epidemiology of CA-MRSA disease in WA is differ-
ent to other regions. Outside of WA the majority of dis-
eases related to CA-MRSA infection are severe skin and
soft tissue infections such as soft tissue abscess, carbun-
cles and furuncles. Many of these infections have
occurred in healthy individuals, especially children and
adolescents, usually via skin-to-skin contact [41]. In WA
the majority of CA-MRSA related diseases were initially
associated with the indigenous population and then
other groups normally susceptible to S. aureus infections
such as the elderly. As the original WA CA-MRSA are
PVL negative, many of these infections were superficial
skin infections such as impetigo. However with the
introduction of the PVL-positive Queensland CA-MRSA
clone more severe skin and soft tissues infections have
been observed.
The limitation of this study is that only the initial iso-
late of each PFGE pulsotype was included in the study.
To determine if the successful CA-MRSA clones found
in the WA community are evolving the genetic profiles
of subsequent isolates need to be investigated.
Conclusions
In conclusion although the vertical and horizontal trans-
mission of SCCmec elements into S. aureus has
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Page 8 of 12occurred on multiple occasions in the WA community
only three WA CA-MRSA clones have found an ecolo-
gical niche. These three PVL negative clones harbor few
additional resistance and virulence genes which para-
doxically may account for their success.
Methods
Isolates
The isolates studied are representative of the 83 CA-
MRSA unique PFGE strains identified in WA from 1989
to 2010 (Figure 3). They include five strains isolated
Dice (Opt:0.50%) (Tol 1.3%-1.3%) (H>0.0% S>0.0%) [0.0%-100.0%]
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Figure 3 Dendrogram of the 83 pulsed-field gel electrophoresis patterns of CA-MRSA isolated in Western Australia.
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Page 9 of 12from indigenous inhabitants living in remote WA rural
communities in 1989 (WA5 {WBG7583} [20]) and 1995
(WA1 {WBG 8287}, WA2 {WB8366}, WA3 {WBG8378},
and WA4 {WBG8404} [42]); and 78 strains identified
from 24,368 CA-MRSA referred to ACCESS Typing and
Research between July 2003 and June 2010.
nuc and mecA
S. aureus species and methicillin resistance was con-
firmed by the detection of nuc (thermostable extracellu-
lar nuclease) and mecA (methicillin resistance) genes by
PCR [43].
Susceptibility testing
An antibiogram was performed by disk diffusion on
Mueller-Hinton agar according to the Clinical and
Laboratory Standards Institute (CLSI) recommendations
[44]. A panel of eight antimicrobial drugs was tested:
erythromycin (15 μg), tetracycline (30 μg), trimethoprim
(5 μg), ciprofloxacin (5 μg), gentamicin (10 μg), rifampin
(5 μg), fusidic acid (10 μg), and mupirocin (5 μg). CLSI
interpretive criteria [45] were used for all drugs except
fusidic acid [46] and mupirocin [47].
PVL
PCR for the detection of PVL determinants was per-
formed as previously described [48].
PFGE
Electrophoresis of chromosomal DNA was performed as
previously described [49], using a contour-clamped
homogeneous electric field (CHEF) DR III system (Bio-
Rad Laboratories Pty Ltd). Chromosomal patterns were
examined visually, scanned with a Quantity One device
(Bio-Rad Laboratories Pty Ltd), and digitally analyzed
using FPQuest (Bio-Rad Laboratories Pty Ltd). S. aureus
strain NCTC 8325 was used as a reference strain.
MLST and spa typing
Chromosomal DNA for MLST and spa typing was pre-
pared using a DNeasy tissue kit (Qiagen Pty Ltd).
MLST was performed as previously described [50].
The sequences were submitted to http://www.mlst.net/
where an allelic profile was generated and an ST
assigned. Clonal complex (CC) was determined using
t h ee B U R S TV 3a l g o r i t h ma tt h es a m ew e b s i t e .C l o n e s
that diverged at no more than one of the seven MLST
loci were considered to belong to the same CC. Double
locus variants (dlvs) were included if the linking single
locus variant (slv) was present in the MLST database.
spa typing, a DNA sequenced-based analysis of the
protein A gene variable region was performed as
previously described [51] using the nomenclature as
described on the Ridom website (http://spa.ridom.de/).
SCCmec typing
The strategy used for SCCmec t y p i n gw a sa sp r e v i o u s l y
described [32]. SCCmec nomenclature is used as pro-
posed by the International Working Group on the Clas-
sification of Staphylococcal Cassette Chromosome
Elements (IWG-SCC) [52]. Briefly, the structural type is
indicated by a Roman numeral, with a lowercase letter
indicating the subtype, and the ccr complex and the mec
complex are indicated by an Arabic numeral and an
uppercase letter respectively in parenthesis. Where there
is an extra ccr element, this is indicated by “&” and an
Arabic numeral designating the ccr type. When there is
an extra ccr element present whose precise location is
unknown it is indicated by an “&” and ccr number out-
side the parentheses.
DNA microarray
Arrays and reagents were obtained from Alere Technolo-
gies, Jena Germany. The principle of the assay, related pro-
cedures, and a list of targets has been described previously
[53,54]. An iterated, linear primer elongation was
employed for the simultaneous amplification of all targets.
An alternative protocol was used for a few isolates in
which amplification and labeling was directed by random
primers [55]. This method detects target genes for which
the binding sites of the primers used in the first protocol
were deleted or changed by nucleotide polymorphisms.
Target genes included species markers, markers for acces-
sory gene regulator (agr) alleles and capsule types, viru-
lence factors, resistance genes, staphylococcal
superantigen-like/exotoxin-like genes (set/ssl genes) and
genes encoding adhesion proteins. Probes for mecA, ugpQ,
xylR, and two probes for mecR were used for SCCmec typ-
ing. The last two probes allowed detection and discrimina-
tion of untruncated mecR and ΔmecR, respectively. Probes
for the recombinase genes ccrA1, ccrB1, ccrA2, ccrB2,
ccrA3, ccrB3, ccrA4, ccrB4,a n dccrC1; the fusidc acid resis-
tance marker Q6GD50; and the J region proteins, dcs, pls-
SCC and the kdp-operon were also included.
MRSA Strain Definition
MRSA strains are defined according to their unique
PFGE pulsotype
MRSA Clone Definition
MRSA clones are defined by the combination of the
multilocus sequence type (ST) and the SCCmec type
[56]. For instance ST1-SCCmec IVa [2B] is abbreviated
as ST1-IVa [2B].
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Additional file 1: Characterisation of CA-MRSA isolated in Western
Australia.
Additional file 2: DNA Microarray Targets, Primers and Probes.
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